Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04087018 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Arcus Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT04087018 is a Phase 1 study that has completed, run by Arcus Biosciences. The registered enrollment target is 18 participants.
The verdict
NCT04087018, a Phase 1 study, has completed, sponsored by Arcus Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a Phase 1b open-label study to evaluate the safety and clinical activity of zimberelimab (AB122) in biomarker-selected participants with advanced solid tumors.
Interventions
- DRUG zimberelimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-09-24 |
| Est. Completion | 2024-06-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04087018
The ClinicalTrials.gov registry entry for NCT04087018 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcus Biosciences, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which zimberelimab is the first listed.
NCT04087018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04087018 about?
NCT04087018 is a clinical study titled "Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors". This is a Phase 1b open-label study to evaluate the safety and clinical activity of zimberelimab (AB122) in biomarker-selected participants with advanced solid tumors.
What is the current status of trial NCT04087018?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2019-09-24. Estimated completion is 2024-06-17.
What interventions are being tested in trial NCT04087018?
The interventions under investigation include: zimberelimab (DRUG).
Who is sponsoring clinical trial NCT04087018?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.